Quest Diagnostics Incorporated
DGX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.95 | -2.77 | -0.39 | 0.22 |
| FCF Yield | 5.43% | 5.59% | 7.24% | 8.46% |
| EV / EBITDA | 12.29 | 11.69 | 12.39 | 8.08 |
| Quality | ||||
| ROIC | 6.96% | 7.75% | 9.83% | 15.26% |
| Gross Margin | 32.86% | 33.17% | 34.74% | 39.02% |
| Cash Conversion Ratio | 1.45 | 1.40 | 1.69 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.04% | -4.99% | 1.55% | 11.77% |
| Free Cash Flow Growth | 5.21% | -34.25% | -28.20% | 15.31% |
| Safety | ||||
| Net Debt / EBITDA | 3.45 | 2.78 | 2.42 | 1.23 |
| Interest Coverage | 5.96 | 7.74 | 9.65 | 15.66 |
| Efficiency | ||||
| Inventory Turnover | 35.26 | 32.63 | 33.59 | 31.63 |
| Cash Conversion Cycle | 42.76 | 36.67 | 36.66 | 40.39 |